Skip to main content
UNCY logo

Unicycive Therapeutics, Inc.

UNCYNASDAQHealthcareBiotechnology

$3.36Today:- (-)1Y −23.78%

As of Oct 16, 2026 close

Market cap
$96.63M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.59$8.74
Volume (live)
-
Avg. volume (3M)
942.42K

Unicycive Therapeutics (UNCY) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Unicycive Therapeutics used $31.32M of cash in operating activities and spent $24.00K on capital expenditures. That left free cash flow of −$31.34M.

Unicycive Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income StatementBalance SheetCash FlowRatios
Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Unicycive Therapeutics, Inc. (UNCY) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2022FY 2022FY 2021FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Mar 2025Dec 2024Dec 2023Mar 2023Dec 2022Mar 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-26.56-36.73-36.73-30.54-18.06-18.06-10.02-10.02-2.26-2.17-1.12
Depreciation & Amortization0.570.430.430.280.160.160.010.010.000.000.00
Stock Based Compensation2.642.352.351.771.051.050.970.970.630.020.00
Change in Working Capital-5.95-0.43-0.43-0.091.181.18-0.11-0.11-0.170.310.01
Change in Accounts Payable-2.510.790.791.281.271.271.241.23-0.070.310.03
Change in Other Working Capital-5.95-1.220.00-0.09-0.090.02-1.353.25-0.100.00-0.03
Other Operating Activities-2.025.800.0010.300.020.023.383.250.050.660.31
Net Cash from Operating Activities-31.32-28.58-28.58-18.28-15.65-15.65-5.77-5.77-1.46-1.18-0.78
Investing Activities
Capital Expenditures-0.02-0.07-0.07-0.010.000.00-0.03-0.030.000.000.00
Purchases of Investments-12.070.00-0.000.00-0.00-0.000.000.00
Net Cash from Investing Activities-12.10-0.07-0.07-0.010.000.00-0.03-0.030.000.000.00
Financing Activities
Debt Repayment0.000.00-0.000.00--0.02-1.36-0.160.000.00
Common Stock Issued46.580.680.680.000.010.0122.2722.270.141.170.25
Dividends Paid0.00-1.10-1.100.000.00-0.00-0.000.000.00
Other Financing Activities-1.6145.50-4.50-2.65-0.48-0.480.12--0.120.000.80
Net Cash from Financing Activities46.4745.0945.0927.54-0.47-0.4722.3822.381.441.170.80
Summary
Net Change in Cash3.0616.4416.449.25-16.12-16.1216.5816.58-0.02-0.010.03
Cash at Beginning of Period26.149.709.700.4616.5816.580.00-0.020.030.00
Cash at End of Period29.2026.1426.149.700.460.4616.5816.580.000.020.03
Free Cash Flow-31.34-28.65-28.65-18.30-15.65-15.65-5.80-5.80-1.46-1.18-0.78
Supplemental Disclosures
Interest Paid--0.010.02-0.01-----
Income Taxes Paid--------0.00--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Unicycive Therapeutics Cash Flow

What is Unicycive Therapeutics's free cash flow?

Unicycive Therapeutics had negative free cash flow of $31.34M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$31.32M minus $24.00K of capital expenditures.

How much does Unicycive Therapeutics spend on capital expenditures?

Unicycive Therapeutics spent $24.00K on capital expenditures in fiscal 2025, compared with $72.00K a year earlier.

Does Unicycive Therapeutics pay dividends or buy back shares?

Unicycive Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition